Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Strongbridge Biopharma plc (SBBP)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 4.7% | 4.9% | 5.4% | 5.1% | 5.1% | 14.5% | 17.6% | 17.6% |
| Gross profit | 95.3% | 95.1% | 94.6% | 94.9% | 94.9% | 85.5% | 82.4% | 82.4% |
| Selling, general and administrative | 159.2% | 130.6% | | 114.2% | 124.2% | 155.9% | | 225.3% |
| Research and development | 53.7% | 69.7% | 64.7% | 83.9% | 79.3% | 113.2% | 143.2% | 132.9% |
| General and administrative | | | 141.1% | | | | 213.5% | |
| EBITDA | -117.4% | -104.9% | -110.9% | -102.9% | -108.3% | -183.2% | -274.0% | -275.4% |
| Depreciation | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% |
| EBITA | -117.6% | -105.2% | -111.1% | -103.2% | -108.5% | -183.5% | -274.3% | -275.8% |
| Amortization of intangibles | 12.5% | 15.0% | 15.3% | 15.5% | 16.2% | 18.8% | 22.4% | 22.1% |
| EBIT | -130.1% | -120.1% | -126.4% | -118.7% | -124.7% | -202.4% | -296.7% | -297.9% |
| Pre-tax income | -131.8% | -140.9% | -145.4% | -39.1% | -222.6% | -190.3% | -160.2% | -230.5% |
| Income taxes | 0.0% | 0.0% | -0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 12.2% |
| Net income | -131.9% | -140.9% | -145.2% | -39.1% | -222.6% | -190.3% | -363.3% | -242.6% |
|